Anzeige
Meldung des Tages: Erste Psilocybin-Behandlungen laufen – warum steht Optimi noch bei Pennystock-Level?!

Transmedics Group News

Aktie
WKN:  A2PH5P ISIN:  US89377M1099 US-Symbol:  TMDX Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  USA
144,92 $
+10,34 $
+7,68%
122,62 € 27.02.26
Depot/Watchlist
Marktkapitalisierung *
3,61 Mrd. €
Streubesitz
-
KGV
61,73
Index-Zuordnung
-

Transmedics Group News

27.02.26 - PR Newswire
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results
TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial ...
24.02.26 - PR Newswire
TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results PR Newswire
20.02.26 - PR Newswire
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
17.02.26 - PR Newswire
TransMedics to Present at Upcoming March Investor Conferences
TransMedics to Present at Upcoming March Investor Conferences PR Newswire
10.02.26 - PR Newswire
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 PR Newswire
09.02.26 - PR Newswire
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial
TransMedics Receives Full and Unconditional FDA IDE Approval for Next-​Generation OCS Heart ENHANCE Trial PR Newswire
12.01.26 - PR Newswire
TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts
TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts PR Newswire
30.12.25 - PR Newswire
TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
24.12.25 - PR Newswire
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
18.11.25 - PR Newswire
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference
TransMedics to Participate in the Piper Sandler 37th Annual Healthcare Conference PR Newswire
31.10.25 - PR Newswire
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
29.10.25 - PR Newswire
TransMedics Reports Third Quarter 2025 Financial Results
TransMedics Reports Third Quarter 2025 Financial Results PR Newswire
15.10.25 - PR Newswire
TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025
TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025 PR Newswire
22.09.25 - PR Newswire
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
TransMedics and Mercedes-​Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy PR Newswire
22.09.25 - PR Newswire
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy
TransMedics and Mercedes-​Benz Announce Strategic Collaboration to Launch First Dedicated Organ Transplantation Ground Transportation Network in Italy PR Newswire
25.08.25 - PR Newswire
TransMedics to Present at Upcoming September Investor Conferences
TransMedics to Present at Upcoming September Investor Conferences PR Newswire
04.08.25 - PR Newswire
TransMedics Receives FDA IDE Approval to Initiate Next-Generation OCS Heart Trial
TransMedics Receives FDA IDE Approval to Initiate Next-​Generation OCS Heart Trial PR Newswire
01.08.25 - PR Newswire
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
30.07.25 - PR Newswire
TransMedics Reports Second Quarter 2025 Financial Results
TransMedics Reports Second Quarter 2025 Financial Results PR Newswire
29.07.25 - PR Newswire
TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference
TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference PR Newswire

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »